Connect with us
DAPA Banner

Crypto World

Hims & Hers (HIMS) Stock Plummets 39% Amid GLP-1 Strategy Shift and Margin Pressure

Published

on

HIMS Stock Card

Key Takeaways

  • In March 2026, Hims & Hers transitioned away from compounded semaglutide to FDA-approved branded GLP-1 medications
  • Bank of America reduced its HIMS price target to $21 from $23 while maintaining a Neutral stance
  • Analysts project GLP-1 EBITDA contributions may decline by 50% compared to last year
  • Amazon Pharmacy launched Eli Lilly’s oral GLP-1 medication Foundayo, intensifying market competition
  • Year-to-date, HIMS shares have plunged approximately 39%, hovering near $20

In a significant strategic shift this March, Hims & Hers abandoned its compounded semaglutide offerings in favor of FDA-sanctioned branded GLP-1 treatments. Management positioned this decision as transforming the company into “the largest global consumer health platform for access to more affordable, approved medications.”


HIMS Stock Card
Hims & Hers Health, Inc., HIMS

This strategic reversal came after settling legal proceedings with Novo Nordisk. The resolution required Hims & Hers to distribute Novo Nordisk’s authorized GLP-1 medications instead of less expensive compounded alternatives.

Investors have responded harshly to these developments. HIMS shares have plummeted nearly 39% year-to-date through Wednesday, currently trading in the vicinity of $20.

BofA Securities analyst Allen Lutz reduced his price objective on HIMS this week from $23 down to $21. The analyst maintained his Neutral stance, pointing to valuation compression among comparable companies and anticipated near-term profitability headwinds.

Lutz’s forecast suggests 2026 EBITDA could land approximately 20% beneath current Wall Street expectations. His analysis indicates GLP-1-related EBITDA contributions might decline by up to 50% compared to the previous year.

Advertisement

Neverthstanding the conservative perspective, Lutz indicated his research team holds “slightly more optimistic” views regarding the company’s overseas expansion strategy. He further observed that the $149 monthly branded GLP-1 subscription plan might eventually deliver margins comparable to compounded options, contingent upon subscriber migration rates.

Subscriber Migration Rates Will Determine Success

BofA Securities projects that Hims & Hers might successfully transition between 40% and 50% of current subscribers to branded medication plans, while maintaining 5% to 10% on compounded alternatives. This conversion scenario would produce approximately $60 million to $90 million in GLP-1 revenues each quarter.

The telehealth platform is simultaneously pursuing international market opportunities. Management targets growing this division beyond $1 billion in annual revenue within a three-year timeframe, achieving mid-teens organic compound annual growth rates. Bank of America’s research into the Eucalyptus platform indicates approximately 90% of revenues will derive from branded GLP-1 distribution at roughly 40% gross profit margins.

Canaccord analyst Maria Ripps offered a more bullish assessment. She maintained her Buy recommendation, contending that the Novo Nordisk collaboration represents a “long-term tailwind” for the business. Ripps believes current valuations fail to recognize the value of the company’s telehealth infrastructure, customer base, and broadening treatment offerings.

Advertisement

Amazon Intensifies Competition With Foundayo Launch

Competitive dynamics became more challenging Thursday when Amazon Pharmacy revealed plans to distribute Eli Lilly’s recently authorized oral GLP-1 medication, Foundayo, featuring same-day delivery options. HIMS shares dipped 0.5% following this announcement. Novo Nordisk declined 1.5%.

Foundayo represents a once-daily oral therapy designed for adults managing obesity or overweight conditions with related health complications. Pricing begins at $25 monthly with insurance coverage, or $149 monthly for self-pay patients.

Amazon will provide same-day delivery across nearly 3,000 metropolitan areas, with plans to extend coverage to 4,500 locations before year-end. The e-commerce giant disclosed it has distributed GLP-1 medications since 2021, with customers saving over $200 million through automated coupon programs, where GLP-1 treatments represent the largest savings category.

Wall Street consensus on HIMS currently stands at Moderate Buy, based on four Buy ratings and 10 Hold ratings issued during the past three months. The mean price target of $26.36 suggests potential upside of approximately 36% from present trading levels.

Advertisement

Source link

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

Trump-Linked Crypto Tokens Face Renewed Scrutiny After Plummeting in Price

Published

on

Donald Trump, Trumpcoin, Memecoin

United States President Donald Trump is facing renewed scrutiny, as crypto tokens and projects promoted by the US president crash to all-time lows or sit near record low levels.

The Official Trump token (TRUMP), a memecoin promoted by Trump, hit an all-time low of about $2.73 in March 2026 and is currently trading at about $2.86, according to data from CoinGecko.

Donald Trump, Trumpcoin, Memecoin
The TRUMP memecoin has plummeted in price since launching in January 2025. Source: CoinGecko

World Liberty Financial (WLFI), a decentralized finance (DeFi) platform co-founded by Trump’s sons, also issued a governance token, which crashed to an all-time low on Saturday, falling to just $0.07.

WLFI is down by nearly 75% from its all-time high of about $0.31 reached in September 2025, while the TRUMP memecoin is down by about 90% since its all-time high of over $73 reached in January 2025. 

Donald Trump, Trumpcoin, Memecoin
The WLFI token has crashed by nearly 75% since the all-time high reached in September 2025. Source: CoinMarketCap

“We thought Sam Bankman-Fried or Gary Gensler were the worst things to happen to the crypto industry, and they were horrible,” Professor Tonya Evans said in response to the plummeting token prices. She added:

“But, turns out, it was the guy who surrounds himself with sycophants, siphons every bit of value he can for himself, and then expeditiously bankrupts companies and casinos without consequence.”

President Trump also announced another gala for token holders, scheduled to take place on April 25, fueling renewed scrutiny from US Democratic lawmakers, who have accused Trump of influence peddling by giving token holders access to him.

Advertisement

Related: Trump memecoin whales pile in ahead of Mar-a-Lago gala

US lawmakers send letter to Trump memecoin creator

Senators Elizabeth Warren, Richard Blumenthal and Adam Schiff recently sent a letter to Bill Zanker, the individual who launched the Trump memecoin, requesting details on the purpose of the planned Trump memecoin gala in April.

The organizers of the event are “dangling access” to Trump, the lawmakers said, according to Politico, which obtained a copy of the letter. 

Trump and his family members stand to benefit from increased sales of the Trump memecoin; attendees are required to hold TRUMP tokens to gain access to the event, the Senators said.

Advertisement

Magazine: Trump’s crypto ventures raise conflict of interest, insider trading questions